Home > Healthcare > Drug Device Combination > Therapeutic Systems > Oncolytic Virotherapy Market

Oncolytic Virotherapy Market Share

Report ID: GMI9645
Published Date: May 2024
Report Format: PDF

Download Free Sample

Oncolytic Virotherapy Market Share

The oncolytic virotherapy industry is moderately fragmented due to the requirement for high capital investments for research and development of oncolytic virus platform. The established vendors have substantial financial and human resources required to conduct capital intensive clinical trials and develop new oncolytic virotherapies, which contributes to their leading market share. The vendors compete in terms of efficacy and early approval and commercialization of their oncolytic virotherapy products.

Oncolytic Virotherapy Market Companies

Prominent players operating in the oncolytic virotherapy industry include:

Amgen Inc.
BioVex, Inc.
Circio Holding ASA
Daiichi Sankyo Company
DNAtrix
Lokon Pharma AB
Medigene AG
Oncolytics Biotech Inc.
PsiOxus Therapeutics
Shanghai Sunway Biotech Co., Ltd.
SillaJen, Inc.
Sorrento Therapeutics
Theriva Biologics
Transgene SA
Virogin Biotech

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncolytic virotherapy industry size was valued at USD 20.1 million in 2023 and is anticipated to showcase growth at 26.9% CAGR from 2024–2032 due to the rising incidence of cancer and increasing investments for developing new oncolytic virotherapies.

The solid tumors segment in the market accounted for USD 12.1 million in 2023 due to the high prevalence of breast, prostate, and lung cancer.

North America oncolytic virotherapy market is expected to reach USD 68.9 million by 2032 due to robust research infrastructure, early adoption of innovative therapies, and increasing awareness among people.

Amgen Inc., BioVex, Inc., Circio Holding ASA, Daiichi Sankyo Company, DNAtrix, Lokon Pharma AB, Medigene AG, Oncolytics Biotech Inc., PsiOxus Therapeutics, Shanghai Sunway and Biotech Co., Ltd., among others.